The Beauty Health Company

NasdaqCM:SKIN Stock Report

Mkt Cap: US$1.5b

We’ve recently updated our valuation analysis.

Beauty Health Valuation

Is SKIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SKIN?

Other financial metrics that can be useful for relative valuation.

SKIN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.5x
Enterprise Value/EBITDA-292.3x
PEG Ratio2.6x

Price to Earnings Ratio vs Peers

How does SKIN's PE Ratio compare to its peers?

The above table shows the PE ratio for SKIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average29.4x
MED Medifast
8.3x-0.2%US$1.2b
HLF Herbalife Nutrition
5.4x1.0%US$1.7b
ELF e.l.f. Beauty
90.3x33.2%US$3.0b
OLPX Olaplex Holdings
13.7x6.2%US$3.8b
SKIN Beauty Health
64.1x25.1%US$1.5b

Price-To-Earnings vs Peers: SKIN is expensive based on its Price-To-Earnings Ratio (64.1x) compared to the peer average (29.4x).


Price to Earnings Ratio vs Industry

How does SKIN's PE Ratio compare vs other companies in the US Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.8%
n/an/an/a

Price-To-Earnings vs Industry: SKIN is expensive based on its Price-To-Earnings Ratio (64.1x) compared to the US Personal Products industry average (19.2x)


Price to Earnings Ratio vs Fair Ratio

What is SKIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SKIN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio64.1x
Fair PE Ratio28x

Price-To-Earnings vs Fair Ratio: SKIN is expensive based on its Price-To-Earnings Ratio (64.1x) compared to the estimated Fair Price-To-Earnings Ratio (28x).


Share Price vs Fair Value

What is the Fair Price of SKIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SKIN ($11.28) is trading above our estimate of fair value ($7.99)

Significantly Below Fair Value: SKIN is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SKIN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.28
US$17.89
+58.6%
35.8%US$32.00US$9.00n/a9
Jan ’24US$9.10
US$18.00
+97.8%
33.8%US$32.00US$9.00n/a10
Dec ’23US$10.87
US$19.33
+77.9%
28.4%US$32.00US$11.00n/a9
Nov ’23US$11.21
US$22.33
+99.2%
14.8%US$31.00US$20.00n/a9
Oct ’23US$11.79
US$22.33
+89.4%
14.8%US$31.00US$20.00n/a9
Sep ’23US$11.38
US$20.89
+83.6%
9.4%US$25.00US$18.00n/a9
Aug ’23US$13.51
US$22.33
+65.3%
10.6%US$25.00US$18.00n/a9
Jul ’23US$12.87
US$22.56
+75.3%
10.7%US$25.00US$18.00n/a9
Jun ’23US$14.07
US$22.78
+61.9%
9.9%US$25.00US$18.00n/a9
May ’23US$13.10
US$27.89
+112.9%
13.2%US$35.00US$23.00n/a9
Apr ’23US$16.91
US$28.44
+68.2%
13.2%US$35.00US$23.00n/a9
Mar ’23US$19.11
US$28.88
+51.1%
17.5%US$35.00US$18.00n/a8
Feb ’23US$14.29
US$30.00
+109.9%
8.3%US$33.00US$27.00n/a8
Jan ’23US$24.16
US$32.00
+32.5%
3.8%US$33.00US$30.00US$9.108
Dec ’22US$24.59
US$32.00
+30.1%
3.8%US$33.00US$30.00US$10.878
Nov ’22US$27.89
US$30.38
+8.9%
10.1%US$33.00US$25.00US$11.218
Oct ’22US$26.50
US$29.17
+10.1%
10.6%US$33.00US$25.00US$11.796
Sep ’22US$27.43
US$27.50
+0.3%
14.5%US$33.00US$23.00US$11.386
Aug ’22US$17.56
US$22.92
+30.5%
17.9%US$31.00US$17.50US$13.516
Jul ’22US$18.05
US$23.10
+28.0%
19.4%US$31.00US$17.50US$12.875
Jun ’22US$15.08
US$16.75
+11.1%
4.5%US$17.50US$16.00US$14.072

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies